Quantcast

Industry news that matters to you.  Learn more

WuXi NextCODE and Fudan Children’s Hospital Partner to Lead Whole Genome Diagnostics for Rare Diseases in China

WuXi NextCODE, a precision medicine company using the genome to improve health worldwide, and the Children’s Hospital of Fudan University (CHFU), based in Shanghai and serving 2.3 million patients nationwide per year, today announced the signing of a landmark agreement for advancing precision medicine in China. It brings WuXi NextCODE’s renowned genomic testing capabilities directly into clinical use for the first time in China, and builds on CHFU’s preeminence in pediatrics to begin immediately to deliver benefits to thousands of rare disease patients across China.

Strand Genomics Inc. And BioHealth Innovation, Inc. Partner To Expand Strand Centers For Genomics & Personalized Medicine In The U.S.

Strand Genomics Inc. (Strand) and BioHealth Innovation, Inc. (BHI) recently announced a strategic partnership designed to expand the Strand Centers for Genomics & Personalized Medicine into the U.S. This effort is intended to help revolutionize access to genomic interpretation services in cardiovascular disease, oncology, rare diseases, and many other indications. Strand Genomics is a wholly owned subsidiary of Strand Life Sciences, a Bangalore, India-based bioinformatics, clinical genomics, and diagnostics company.

University of Cambridge, Genomics England Ltd., and Illumina Collaborate to Sequence 10,000 Whole Human Genomes for National Health Service Patients

University of Cambridge, Genomics England Ltd., and Illumina, Inc. (NASDAQ:ILMN) recently announced the start of a three-year project that will sequence 10,000 whole genomes of children and adults with rare genetic diseases. The project represents a pilot for Genomics England Ltd., which will provide 2,000 samples, and marks the beginning of the national endeavor to sequence 100,000 genomes in the UK National Health Service (NHS), announced recently by the Prime Minister, David Cameron.

SV Bio Launched as First Diagnostics Company to Provide Turnkey Translation of Comprehensive Genomics Data at Point of Care

Silicon Valley Biosystems (SV Bio), a diagnostics company founded to provide rapid, accurate, and turnkey clinical interpretation of comprehensive genomics data at the point of care to improve the health and outcomes of patients, was launched today. Backed by Sequoia Capital, a premier venture capital firm that helped to build Apple, Google, LinkedIn, Oracle and numerous biotech companies, SV Bio is ushering in the next phase of genomics-based medicine by providing clinicians with the tools they need to make faster, more precise and cost-saving decisions.

Ingenuity Variant Analysis Enables Rapid Identification of Causal Variants From Human Resequencing Studies

Ingenuity Systems, a leading provider of information and analysis solutions for life science researchers, today announced the general availability of Ingenuity Variant Analysis, a web application designed to help researchers studying human disease rapidly identify causal variants from human resequencing data. Researchers can quickly and reliably take a list of millions of variants down to the most compelling set of variants for follow-up study and analysis.